BRIDGEWATER, N.J., Nov. 1, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced that the underwriters of its October 22, 2010 initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of Aegerion's common stock at $9.50 per share, less underwriting discounts and commissions. The option was granted in connection with Aegerion's initial public offering of 5,000,000 shares. The over-allotment option is expected to close on November 2, 2010, subject to customary closing conditions.
Including the over-allotment shares, a total of 5,750,000 shares will have been sold in the offering, resulting in net proceeds of approximately $48.8 million, after deducting underwriting discounts and commissions and estimated offering expenses.
The joint book-running managers of the initial public offering were Leerink Swann LLC and Lazard Capital Markets LLC. The co-managers were Needham & Company, LLC, Canaccord Genuity Inc. and Collins Stewart LLC.
A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission (SEC) on October 22, 2010. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Copies of the final prospectus for the offering may be obtained from Leerink Swann LLC by mail at One Federal Street, 37th Floor, Boston, MA 02110, Attention: Syndicate Department, or by calling toll free (800) 808-7525, Ext. 4814, or from Lazard Capital Markets LLC by mail at 30 Rockefeller Plaza, 60th Floor, New York, NY 10020, Attention: Syndicate Department, or by calling toll free (800) 542-0970.
Aegerion Pharmaceuticals is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders. The Company's lead product candidate is a small molecule, oral therapy being developed for patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH.
CONTACT: Aegerion Phamaceuticals, Inc. Corporate Will Lewis, President +1 (908) 704-1300 LaVoie Group, Inc. Investors & Media Liz Pingpank +1 (978) 745-4200 x104 email@example.com